erythropoietin

(redirected from recombinant human erythropoietin)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia.

e·ryth·ro·poi·e·tin

 (ĭ-rĭth′rō-poi-ē′tĭn)
n.
1. A glycoprotein hormone that stimulates the production of red blood cells by stem cells in bone marrow. Produced mainly by the kidneys, it is released in response to decreased levels of oxygen in body tissue.
2. Epoetin alfa.

[erythropoiet(ic) + -in.]

erythropoietin

(ɪˌrɪθrəʊpɔɪˈiːtɪn)
n
(Biochemistry) a hormone, secreted by the kidney in response to low levels of oxygen in the tissues, that increases the rate of erythropoiesis. It has been used as a performance-enhancing drug for athletes and racehorses. Abbreviation: EPO

e•ryth•ro•poi•e•tin

(ɪˌrɪθ roʊˈpɔɪ ɪ tn, -pɔɪˈit n)

n.
a hormone that stimulates production of red blood cells and hemoglobin in the bone marrow.
[1945–50]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.erythropoietin - a glycoprotein secreted by the kidneys that stimulates the production of red blood cells
glycoprotein - a conjugated protein having a carbohydrate component
Translations
EpoetinErythropoetinErythropoietinHämatopoetin
eritropoietina

e·ryth·ro·poi·e·tin

[MIM*133170]
n. eritropoyetina, proteína no dializable que estimula la producción de eritrocitos.

erythropoietin

n eritropoyetina
References in periodicals archive ?
The impact of recombinant human erythropoietin treatment on motor impairment in rotenone-induced parkinsonism in rats.
Recombinant human erythropoietin increased the expression of CD34 and vascular endothelial growth factor receptor 2 through phosphatidylinositol 3 kinase/Akt pathway
Daprodustat will be evaluated in the two studies whether it is non-inferior or not to recombinant human erythropoietin on the endpoints considered as the primary analysis.
The report covers the present scenario and the growth prospects of the recombinant human erythropoietin (rhEPO) market in China for 2016-2020.
Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration.
Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.
All investigations were done on day one before the start of therapy, and then treatment was initiated with recombinant human erythropoietin in a dose of 5000 IU subcutaneously and injection Iron Sucrose 200mg in 100cc NaCl intravenously on 3 alternate days.
Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin.
EPO, or recombinant human erythropoietin (rhEPO), increases endurance by boosting the number of oxygencarrying red blood cells.
As a result, recombinant human erythropoietin has become the gold standard in treating anemia of chronic renal insufficiency.

Full browser ?